Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 243.55 Bil Enterprise Value: 363.97 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 75/100

Royalty Pharma PLC at UBS Global Healthcare Conference Transcript

May 24, 2022 / 05:15PM GMT
Release Date Price: MXN783
Colin Bristow

Good afternoon, everyone, and thank you for attending the UBS Global Healthcare Conference. I'm Colin Bristow, one of the biotech analysts here. It is my pleasure to have with us today, Royalty Pharma. From Royalty, we have Marshall Urist, EVP and Co-Head of Research and Investments; and Chris Hite, EVP and Vice Chairman. Thank you for joining us today.

Christopher Hite
Royalty Pharma plc - Executive VP & Vice Chairman

Thank you.

Marshall Urist
Royalty Pharma plc - Executive VP and Head of Research & Investments

Thanks, Colin.

Colin Bristow

(Operator Instructions) There we go. So I know you have some opening remarks. So I'll let you take it away, and then we'll dig into some of the questions.

Christopher Hite
Royalty Pharma plc - Executive VP & Vice Chairman

Okay. Great. I think Marshall and I will do a quick spin through some slides and then obviously open up to Q&A. So -- but thank you very much for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot